Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. [electronic resource]
Producer: 20170403Description: 403-17 p. digitalISSN:- 1179-2027
- Antiviral Agents -- economics
- Benzimidazoles -- economics
- Cost-Benefit Analysis
- Drug Costs
- Drug Therapy, Combination -- economics
- Fluorenes -- economics
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Interferon-alpha -- economics
- Markov Chains
- Models, Statistical
- Polyethylene Glycols -- economics
- Quality-Adjusted Life Years
- Recombinant Proteins -- economics
- Ribavirin -- economics
- Sofosbuvir
- South Africa
- Uridine Monophosphate -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.